ClearPoint Neuro (NASDAQ:CLPT) Reaches New 12-Month High – Time to Buy?

ClearPoint Neuro, Inc. (NASDAQ:CLPT) shares hit a new 52-week high on Thursday . The stock traded as high as $29.87 and last traded at $29.60, with a volume of 1331006 shares changing hands. The stock had previously closed at $26.39.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of ClearPoint Neuro in a report on Wednesday. Stifel Nicolaus increased their price objective on ClearPoint Neuro from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Finally, Wall Street Zen upgraded ClearPoint Neuro from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $19.67.

ClearPoint Neuro Stock Down 9.8%

The company has a quick ratio of 6.45, a current ratio of 7.30 and a debt-to-equity ratio of 1.46. The company’s fifty day simple moving average is $14.33 and its 200 day simple moving average is $12.93. The firm has a market capitalization of $742.31 million, a PE ratio of -32.23 and a beta of 1.19.

ClearPoint Neuro (NASDAQ:CLPT) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The company had revenue of $9.22 million during the quarter, compared to analysts’ expectations of $9.20 million. ClearPoint Neuro had a negative return on equity of 94.44% and a negative net margin of 66.15%. ClearPoint Neuro has set its FY 2025 guidance at EPS. Analysts anticipate that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ClearPoint Neuro

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. lifted its position in ClearPoint Neuro by 98.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 257,871 shares of the company’s stock valued at $3,066,000 after acquiring an additional 127,823 shares during the period. Lane Generational LLC lifted its holdings in shares of ClearPoint Neuro by 53.5% during the first quarter. Lane Generational LLC now owns 242,045 shares of the company’s stock valued at $2,878,000 after purchasing an additional 84,350 shares during the last quarter. Two Sigma Investments LP purchased a new position in shares of ClearPoint Neuro during the fourth quarter valued at approximately $159,000. Deutsche Bank AG purchased a new position in shares of ClearPoint Neuro during the first quarter valued at approximately $63,000. Finally, Conway Capital Management Inc. lifted its holdings in shares of ClearPoint Neuro by 31.1% during the first quarter. Conway Capital Management Inc. now owns 211,325 shares of the company’s stock valued at $2,513,000 after purchasing an additional 50,100 shares during the last quarter. Hedge funds and other institutional investors own 30.08% of the company’s stock.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.